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Figure 1. Cumulative incidence: time to ANC >500.
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Background: The binding of CXCR4 with its ligand (stromal
derived factor-1 [SDF-1]) maintains hematopoietic stem/pro-
genitor cells (HSPCs) in a quiescent state. This effect of CXCR4/
SDF-1 interaction may be undesirable during the early phase
of hematopoietic stem cell transplantation (HSCT). We hy-
pothesized that blocking CXCR4/SDF-1 interaction after HSCT
promotes hematopoiesis by inducing HSPC proliferation. WeFigure 2. Cumulative incidence: time to platelet >20.have found that giving AMD3100 (plerixafor) after HSCT
enhanced recovery of all donor cell lineages in murine
transplant models (Kang, PLOS ONE 2010). We have further
demonstrated that this enhanced donor cell recovery results
from the combined effect of AMD3100 opening the marrow
niche and inducing HSPC cell division. Based on these ﬁnd-
ings, we conducted a phase I/II trial of plerixafor on donor cell
recovery following myeloablative allogeneic HSCT.
Methods: Patients with various hematologic malignancies
receiving myeloablative conditioning were enrolled in the
study. Plerixafor 240 mg/kg subcutaneously every other day
was administered beginning day +2 until day +21 or until
ANC>500. The primary efﬁcacy endpoints of the study were
time to ANC>500 and time to platelets>20k. The cumulative
incidence of neutrophil and platelet engraftment of the study
cohort was compared to that of a historical cohort of 106
patients from the Duke HSCT program who received similar
conditioning and graft-versus host disease prophylaxis. Pre-
engraftment relapse and death were the competing risks.
Gray’s test was used to compare the cohorts.
Results: Twenty-nine patients were evaluated in the study.
Adverse events attributable to plerixafor were mild in nature
and expected (GI upset, nausea, diarrhea, fatigue, and in-
jection site reactions). They were difﬁcult to distinguish from
effects of the myeloablative conditioning regimen. There
were no dose limiting toxicities of premature ventricular
arrhythmias, primary or secondary graft failure, or mortality
associated with plerixafor administration. Engraftment ki-
netics as demonstrated by cumulative incidence showed a
trend toward faster neutrophil engraftment (p¼0.07) and
quicker platelet recovery >20K (p¼0.04) Figures 1 and 2.
Median time to ANC>500 with 95% CI for plerixafor treat-
ment group and historical control group was 17 days (16, 18)
and 17 days (16, 19), respectively. Median time to platelet
count >20 was 18 days (15, 22) in the treatment cohort and
19 days (19, 21) historically. Transplant related mortality
calculated at Day +100 with 95% CI was 0.069 (0.00, 0.157).
Conclusion: In this study, there appeared to be limited tox-
icities with plerixafor following myeloablative HSCT. Plerix-
afor enhances platelet recovery, and may enhance neutrophil
recovery as well. This study provides proof of principle that
blocking CXCR4 after HSCT enhances hematopoietic recovery.
Larger, conﬁrmatory studies are justiﬁed.11
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Background: Currently, the thalassemia free survival rate
after hematopoietic stem cell transplant (HSCT) is about 80-
90%with either matched sibling or unrelated donor. However,
the probability to ﬁnd a suitable door is only 25-50%. Since
most of these patients (pts) could not ﬁnd the potential donor,
we would like to investigate the haplo-SCT in thalassemia.
Patients and Methods: Between Jan 2013 and October 2014,
15 thalassemia patients (pts) underwent haplo-SCT. Eight
subjects were male and 7 were female. The median age was
16 yrs (range; 2-22). Eleven of 15 received stem cells from
mother and 4 from father. Twelve of 15were high risk class 3.
Table
Characteristics and outcomes of the participants (n¼409)
Variable No. (%) Mean  SD
Age, yr 52.3  12.3
Range 18.2 d 75.2
Male 257 (63)
KPS 86  6
6MWD, m 404 113
Range 71 d 737
EF 62  5
ECHO 297 (73)
MUGA 105 (26)
Other 4 (1)
Unavailable 3 (>1)
DLCO 82.4  17.97
Tumor type d no. (%)
AML 150 (37)
ALL 32 (8)
Other acute leukemia 5 (1)
CML 13 (3)
NHL/CLL 104 (25)
HD 13 (3)
MDS/MPD 54 (13)
MM 35 (9)
Other 3 (1)
1st Allogenic transplant 401 (98)
Conditioning regimen intensity
MA 266 (65)
Rl 69 (17)
NMA 74 (18)
Donor type
Matched related 139 (34)
Mismatched related 1 (<1>
Matched unrelated 147 (36)
Mismatched unrelated 62 (15)
Cord or cord/haplo 60 (15)
Source
Bone marrow 12 (3)
Peripheral blood 337 (82)
Cord or cord/haplo 60 (15)
Manipulation
Unmodiﬁed 140 (34)
TCD 209 (51)
Cord or cord/haplo 60 (15)
Follow up for survivors, months 35  15
Range 3 d 61
Relapse 70 (17)
Causes of death
Relapse 70 (40)
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d for at least 3 months prior to HSCT. All pts received 2
courses of pre-transplant immunosuppression (PTIS) con-
sisting of ﬂudarabine (Flu) 40 mg/m2/d together with dexa-
methasone (dex) 25 mg/m2/d for 5 days. After 2 courses of
PTIS, all pts received a reduced-toxicity conditioning
regimen consisting of thymoglobulin 1.5 mg/kg/d (d-11 to
d-9), Flu 35 mg/m2/d i.v. (-7 to -2) each dose immediately
followed by busulfan (Bu) 130 mg/m2once daily i.v. (d-7 to
d-4) for pts > 10 years and 0.95-1.2 mg/kg every 6 hr (d-7 to
d-4) for pts < 10 yrs. GVHD prophylaxis consisted of cyclo-
phosphamide (Cy) 50 mg/kg/d (d+3 to d+4). Tacrolimus was
given for 6 months to 1 yr started together with mycophe-
nolate mofetil on d+5, the latter was quickly tapered after 2
months. T-cell repleted peripheral blood stem cells were
given to all pts targeting a CD34+ dose of 7-10 x 106 cells/kg.
Results: Fourteen of 15 were engrafted with full donor
chimerism (100%) while one pt suffered graft failure. How-
ever, this pt received second transplant on day +30 with
minimal conditioning regimen and additional PBSC, after
which she achieved full donor chimerism. The median time to
neutrophil engraftment was 18 days (range; 14 -22). Six pts
had acute GVHD gr I, 3 grade II and1 gr III. Only one had
limited chronic GVHD. At this time, all 15 pts survive thalas-
semia-free and have sustained full donor chimerism (100%).
The thalassemia free survival and overall survival rates are
100%. Themedian follow up timewas 12months (range 4-22).
Conclusion: Haplo-SCT for high risk thalassemia pts with
our novel approach is safe, and should be considered as a
modality to secure thalassemia-free survival with a low risk
of graft rejection and treatment-related mortality. With this
result, our Haplo-SCT in thalassemia pts has favorable
outcome as related and unrelated HSCT (thalassemia free
survival rate> 90%). In viewof our results, we suggest that all
thalassemia pts even those with high risk class 3 features
should be offered the chance for cure with HSCT.
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Transplant Risk Assessment Among Patients Undergoing
Allogeneic Hematopoietic Cell Transplantation
Lee W. Jones 1, Sean Devlin 2, Molly Malroy 1,
Noel Espiritu 1, Jennifer Aquino 1, Ceceile Hall 1,GvHD 46 (26)
Infection 30 (17)
Graft failure 7 (4)
Toxicity 3 (2)
Other 18 (10)
Abbreviations: BMI, body mass index; KPS, Karnofsky Performance Sta-
tus; 6MWD, six minute walk distance; AML, Acute Myelogenous Leuke-
mia; ALL, Acute Lymphoblastic Leukemia; CML, Chronic Myelogenous
Leukemia; NHL/CLL, Non Hodgkin Lymphoma/Chronic Lymphocytic Leu-
kemia; HD, Hodgkin Lymphoma, MDS/MPD, Myelodysplastic Syndrome/
Myeloproliferative Disorder; MM, Multiple Myeloma; MA, Myeloablative;
RI, Reduced Intensity; NMA, Non Myeloablative; TCD, T Cell Depleted.
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Background: Identiﬁcation of patients at high risk of he-
matopoietic cell transplantation (HCT)-related complications
